Highest-materiality recent filing
Arcellx completes acquisition by Gilead Sciences subsidiary for $115 per share plus CVR
Tender offer expired with 38,795,604 shares tendered, representing ~77.2% of outstanding shares.
Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B
Per-share consideration: $115 cash at closing + one CVR worth up to $5 contingent on anito-cel cumulative sales exceeding $6B by Dec 31, 2029.
Arcellx: anito-cel achieves 96% ORR, 74% CR/sCR in pivotal RRMM study
96% ORR (112/117) and 74% CR/sCR (86/117); 95% MRD negativity (91/96) at 10^-5 sensitivity.
Arcellx Q3 2025 net loss widens to $55.8M; collaboration revenue drops 81%
Cash, equivalents, and marketable securities of $576.0M as of Sep 30, 2025; expected to fund operations into 2028.
Arcellx reports 97% ORR from anito-cel Phase 2; FDA clears ACLX-004 IND; Q2 net loss $52.8M
Phase 2 iMMagine-1: 97% ORR, 68% CR/sCR at 12.6 months; no delayed neurotoxicity events observed.
Arcellx shareholders elect three Class III directors, approve say-on-pay, and ratify PwC
Rami Elghandour, David Lubner, and Kristin Myers elected as Class III directors with 42.8M, 38.9M, and 49.3M votes for, respectively.
Arcellx reports 97% ORR and 68% CR/sCR in Phase 2 anito-cel study for RRMM
Phase 2 iMMagine-1 (117 patients) showed 97% ORR and 68% CR/sCR at median 12.6 months follow-up.
Arcellx Q1 net loss $62.3M; cash $565M; iMMagine-3 adds MRD endpoint
Net loss of $62.3M vs $7.2M in Q1 2024; collaboration revenue down to $8.1M from $39.3M.
Arcellx appoints Andrew Galligan and Kristin Myers to board; Derek Yoon resigns
Derek Yoon resigned from the board effective March 18, 2025; no disagreements.
Arcellx FY2024 net loss $107.3M; anito-cel Phase 2 shows 97% ORR, 62% CR/sCR
Cash, equivalents, and marketable securities $625.7M; runway into 2027.
Arcellx reports positive Phase 2 anito-cel data for relapsed/refractory multiple myeloma at ASH 2024
Hosted investor webcast at ASH highlighting new positive data from Phase 2 pivotal iMMagine-1 study of anito-cel.
Arcellx iMMagine-1 study: 97% ORR, 62% CR/sCR, no delayed neurotoxicity in RRMM
Phase 2 pivotal iMMagine-1: 86 patients evaluable; ORR 97% (83/86), CR/sCR 62% (53/86) at median 9.5-month follow-up.
Arcellx Q3 net loss narrows; anito-cel hits 95% ORR in pivotal study with no neurotoxicity
Q3 net loss $25.9M ($39.3M YoY); collaboration revenue $26M from Kite expansion.
Arcellx updates anito-cel data: Phase 1 median PFS 30.2 months; iMMagine-1 95% ORR
Phase 1 study (38 patients): 100% ORR, 79% CR/sCR, median PFS 30.2 months at 38.1 months median follow-up; median OS not reached.
Arcellx Q2 net loss $27.2M; earns $68M milestone from Kite; IND cleared for myasthenia gravis
Earned $68M milestone from Kite for iMMagine-1 enrollment in multiple myeloma.
Arcellx shareholders re-elect three directors; say-on-pay approved with 56% support
Jill Carroll, Kavita Patel, Olivia Ware re-elected as Class II directors through 2027.
Arcellx Q1 net loss narrows to $7.2M; collaboration revenue rises to $39.3M
Cash, cash equivalents, and marketable securities of $691.0M as of March 31, 2024; funds operations into 2027.
Arcellx dismisses EY, appoints PwC as independent auditor for FY 2024
Board dismissed Ernst & Young as independent auditor on March 8, 2024; no disagreements on accounting principles.
Arcellx posts Q4 net income of $20.5M, cash $729.2M, expands Kite partnership
Q4 2023 net income $20.5M vs net loss $39.0M in Q4 2022; full-year net loss narrowed to $70.7M from $188.7M.
Arcellx assigns Gaithersburg lease, moves HQ to Redwood City, CA
On Jan 30, 2024, Arcellx assigned its Gaithersburg, MD lease to a third-party sublessee.
Arcellx closes $200M Gilead investment and license amendment with Kite
Closed transactions: issued 3,242,542 shares to Gilead for $200 million aggregate.
Arcellx presents CART-ddBCMA Phase 1 expansion data at ASH; no specific results disclosed in 8-K
Event at 65th ASH Annual Meeting on Dec 11, 2023 in San Diego highlighting CART-ddBCMA Phase 1 expansion trial.
Arcellx anito-cel Phase 1 shows 100% ORR, 76% CR; median PFS 28 months at 26.5 mo follow-up
100% ORR (38/38) with 76% achieving CR/sCR; median PFS estimated at 28 months with 26.5 mo median follow-up.
Arcellx expands Kite partnership: $85M upfront, $200M equity at $61.68/sh; cash runway to 2027
Kite exercises option for ARC-SparX program ACLX-001 in multiple myeloma; collaboration expanded to lymphomas for CART-ddBCMA.
Net loss narrowed to $39.3M from $92.9M in Q3 2022; collaboration revenue $15.0M from Kite license.
Arcellx reports 100% ORR, 76% CR rate in Phase 1 CART-ddBCMA trial; median follow-up 22 mo
Overall response rate 100% per IMWG criteria; 29/38 patients (76%) achieved CR or sCR.
Arcellx FDA partial clinical hold lifted for iMMagine-1; Q2 net loss $23.9M
FDA lifted partial clinical hold on CART-ddBCMA Phase 2 iMMagine-1 trial after patient death and protocol modifications.
Arcellx receives FDA clinical hold on CART-ddBCMA after patient death in Phase 2 trial
FDA placed clinical hold on CART-ddBCMA IND for relapsed/refractory multiple myeloma on June 16, 2023, after a recent patient death.
Arcellx shareholders re-elect directors, approve charter amendment, ratify auditor
Re-elected Ali Behbahani with 24.7M for, 16.8M withhold; Derek Yoon with 40.8M for, 0.7M withhold.
Arcellx Q1 2023: cash $533.6M; collaboration revenue $17.9M; net loss $27.3M
Cash, cash equivalents and marketable securities $533.6M; expected to fund through BLA filing in H1 2025.
Arcellx enters into $350M at-the-market equity offering agreement with Stifel
Arcellx may sell up to $350M of common stock through Stifel in at-the-market offerings.
Arcellx reports 2022 results; announces Kite collaboration for CART-ddBCMA with $325M upfront
Strategic collaboration with Kite (Gilead): $225M upfront + $100M equity; co-commercialize in US, royalties ex-US.
Arcellx closes collaboration with Kite/Gilead for CART-ddBCMA; sells $100M of stock to Gilead
Global collaboration to co-develop and co-commercialize CART-ddBCMA for relapsed/refractory multiple myeloma.
Board amended and restated bylaws effective December 15, 2022, revising director nomination and stockholder proposal procedures.
Arcellx and Kite Pharma enter CAR T-cell therapy collaboration; $225M upfront + $100M equity
Collaboration and License Agreement with Kite Pharma (Gilead) for CART-ddBCMA, a CAR T therapy for myeloma.
Arcellx and Kite (Gilead) partner on CART-ddBCMA; $225M upfront + $100M equity; 100% ORR in Phase 1
Arcellx receives $225M upfront cash and $100M equity investment from Gilead; eligible for up to $3.9B in milestones.
Arcellx Q3 net loss $92.9M; initiates pivotal iMMagine-1 study for CART-ddBCMA
Net loss of $92.9M vs $17.1M in Q3 2021, driven by $63.1M non-cash Lonza lease expense.
Arcellx overstates R&D expense by $6.3M in Q1 2022, $7.7M in H1 2022; prior financials non-reliable
Audit Committee concludes Q1 and Q2 2022 financials no longer reliable due to R&D expense accounting errors.
Arcellx Q2 net loss $32.1M; cash $307M; CART-ddBCMA shows 100% ORR
Net loss $32.1M vs $15.9M YoY; R&D spend $23.4M; G&A $9.2M.
Arcellx closes upsized public offering of 8.05M shares, gross proceeds $128.8M
Offered 7M shares plus full underwriter option of 1.05M; total 8.05M at $16.00 per share.
Arcellx appoints Michelle Gilson as CFO effective May 23, replacing interim CFO
Michelle Gilson named CFO, principal financial and accounting officer, effective May 23, 2022.
Arcellx appoints Olivia Ware to board, replacing Lewis T. Williams effective May 16
Lewis T. Williams resigned from board effective May 16, 2022; no disagreement cited.
Arcellx Q1 net loss $32.4M; CART-ddBCMA 100% ORR; doses first ACLX-001 patient
Q1 net loss $32.4M (vs $11.3M Q1 2021); R&D expense $24.4M (+$15.9M).
Arcellx posts $65M FY2021 net loss; IPO cash extends runway into H2 2023
Net loss for FY2021 was $65.0M vs $32.1M in 2020; Q4 net loss $20.7M vs $9.1M.
Arcellx enters $24.5M manufacturing SOW with Lonza for CART-ddBCMA
Statement of work effective Feb 16, 2022 for technology transfer and cGMP manufacturing of CART-ddBCMA and other pipeline products.
Arcellx closes IPO of 9.49M shares at $15/sh, gross proceeds $142.3M
IPO closed with 9,487,500 shares, including full exercise of underwriters' option for 1,237,500 shares.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
each officer of the Company resigned and ceased to be an officer of the Company as of the Effective Time.
the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.
the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.
the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.
Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.
Max materiality 1.00 · Median 0.72 · Most common event other_material